Bringing innovation and technology to the patient-care journey
As part of Kyowa Kirin’s Commitment to Life, we have a focus in Australia on rare diseases and their treatments. We want to become a trusted partner to patients, carers, healthcare professionals and other stakeholders in this arena.
Embarking on a journey that is less visited
Kyowa Kirin aims to deliver innovative technology in Australia’s rare disease space. We work with our global team to bring in pharmaceutical candidates, using state-of-the-art technologies for the following treatment areas.
As a company rich in culture and diversity, we welcome and are flexible to strategic collaborations and partnerships with pharmaceutical firms, biotechnology companies, and academia partners in rare disease.
Cutaneous T-cell Lymphoma (CTCL)
One area of such focus is Cutaneous T-cell Lymphoma (CTCL), an ongoing unmet need. This haematological cancer initially affects the skin but then can also involve the blood, lymph nodes, and other internal organs.
Ref: Australian Clinical Practice Statement: MYCOSIS FUNGOIDES AND SEZARY SYNDROME. July 2020
X-linked hypophosphataemia (XLH)
Another area is X-linked hypophosphataemia (XLH), a rare genetic disorder which causes phosphate wasting, and affects children and adults. The progressive and compounding symptoms of XLH lead to skeletal defects, muscular dysfunction, and dental abnormalities.
Ref: Haffner et al. Nat Rev Nephrol. 2019 Jul;15(7):435-455
Making the journey count
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialisation, driven by state-of-the-art antibody technologies, in the core therapeutic areas of Nephrology, Oncology, Immunology & Allergy, and Central Nervous System.
Cutting-edge biotechnology centered on antibody engineering technology
Technology-driven Drug Discovery
Within Kyowa Kirin, our team of experts firmly supports and infuses exquisite experience and technologies when it comes to novel drug discoveries. We practice this across all disciplines revolving around research, development, and manufacturing of biologics, and open innovation. This unique style of drug discovery is what we call technology-driven drug discovery.